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At a Glance Commentary 
Scientific Knowledge on the Subject: Despite observational studies suggesting that COPD 
exacerbation can be detected using a combination of symptoms and physiological measures, 
such as pulse and oxygen saturation, larger randomized controlled trials have not shown any 
effect of telemonitoring on time to first hospital admission (TTFH), hospitalization and quality 
of life. Tested tele-monitoring programs had a negligible impact on healthcare costs, and, in 
some cases, resulted in an increased healthcare utilisation. 
What This Study Adds to the Field: This randomized controlled trial of 312 COPD patients is 
the first using only objective lung function data measured daily by the forced oscillation 
technique to prompt early intervention. Despite being feasible and well accepted by patients, 
this approach did not affect TTFH and quality of life. However, it significantly reduced 
healthcare costs, mostly due to a reduction in duration and frequency of subsequent 
hospitalisations, which was greatest in patients hospitalised the year before recruitment. 
 
This article has an online data supplement, which is accessible from this issue's table of content 
online at www.atsjournals.org 
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Abstract  
Rationale Early detection of COPD exacerbations using tele-monitoring of physiological variables 
might reduce the frequency of hospitalisation. 
Objectives To evaluate the efficacy of home monitoring of lung mechanics by the forced oscillation 
technique (FOT) and cardiac parameters in older COPD patients with co-morbidities. 
Methods This multicentre, randomized clinical trial recruited 312 GOLD grade II-IV COPD patients 
(median age 71 years [IQR:66-76], 49.6% grade II, 50.4% grade III-IV),  with a history of 
exacerbation in the previous year and at least one non-pulmonary co-morbidity. Patients were 
randomised to usual care (n=158) or tele-monitoring (n=154) and followed for 9 months. All tele-
monitoring patients self-assessed lung mechanics daily and in a subgroup with congestive heart 
failure (n=37) cardiac parameters were monitored. An algorithm identified deterioration, triggering a 
telephone contact to determine appropriate interventions. 
Measurements and Main results Primary outcomes were time to first hospitalisation (TTFH) and 
change in EQ-5D utility index score. Secondary outcomes included: rate of antibiotic/corticosteroid 
prescriptions, hospitalisation, CAT, PHQ-9 and MLHF questionnaire scores, quality-adjusted life 
years and healthcare costs. Tele-monitoring did not affect TTFH, EQ-5D utility index score, antibiotic 
prescriptions, hospitalization rate and questionnaire scores. Tele-medicine was associated with fewer 
repeat hospitalizations (-54%, p=0.017). Previously hospitalised patients showed the greatest 
reduction in hospitalization rate (-53%, p=0.017) with large potential for cost savings (-
3736€/patient/year, p=0.010).  
Conclusions In older COPD patients with co-morbidities remote monitoring of lung function by FOT 
and cardiac parameters did not change TTFH and EQ-5D.  However patients at risk of hospitalisation 
may benefit from this approach.  
Keywords: Forced Oscillation technique, FOT, COPD exacerbation, Chronic Obstructive Pulmonary 
disease, Home monitoring, Chronic Obstructive Pulmonary Disease 
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Introduction 
Chronic obstructive pulmonary disease (COPD) is common, impairs quality of life and is a 
leading cause of death worldwide1. Co-morbid conditions, such as cardiovascular disease often co-
exist with COPD, leading to worse outcomes2. Both co-morbidity and increasing age are associated 
with less effective COPD self-management3, more frequent hospitalisation4 and higher mortality5–7.  
The Global Initiative for Chronic Obstructive Lung Disease (GOLD) guidelines use frequency 
of exacerbation and hospitalization to stratify risk and direct treatment for COPD patients and 
consider exacerbation reduction as a core management goal1. Pharmacological therapy1, pulmonary 
rehabilitation8 and influenza vaccination9 all reduce the exacerbation rate but their impact is modest. 
The use of remote tele-monitoring to detect exacerbations early is attractive as it might reduce 
exacerbation duration, severity and the need for hospitalization, a major driver of healthcare costs 10. 
To date, most tele-monitoring studies in COPD have monitored symptoms and simple physiological 
measures, such as heart rate and oxygen saturation, alongside enhanced clinical support11–15 and only 
a few included physiological measurements such as peak expiratory flow rate16. The outcomes of 
these studies have been disappointing, with limited evidence of health or economic benefit12,17. 
Moreover, none included objective, effort-independent measurements of pulmonary function. 
The Forced Oscillation Technique (FOT) measures the mechanical properties of the lung 
during tidal breathing in a way that is simple to perform without supervision or effort, is operator 
independent and can be undertaken at home by COPD patients18,19. FOT can also detect changes in 
lung mechanics acutely after a bronchodilator20 and during recovery from an exacerbation21–23, 
making it a potentially attractive way to objectively define exacerbation events in  a telemonitoring 
programme.  
We hypothesised that, in older patients with both COPD and co-morbidities, remote 
respiratory monitoring using daily FOT measurements, with or without enhanced cardiac monitoring, 
would reduce the time to first hospitalization (TTFH), increase quality of life and reduce healthcare 
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costs. To test this hypothesis we conducted the CHROMED (Clinical tRials fOr elderly patients with 
MultiplE Disease) study, an international randomised controlled trial funded by the European 
Commission (CHROMED, project ID: 306093). 
 
Methods 
CHROMED was a multicentre, randomized unblinded parallel group clinical trial. Patients 
were recruited at six sites in five countries: Spain, UK, Slovenia, Estonia and Sweden (see ONLINE 
DATA SUPPLEMENT for details). The study was registered on ClinicalTrials.gov: NCT01960907. 
Patients 
We recruited patients aged 60 years or older, with a diagnosis of COPD GOLD grade II or 
higher24, a history of acute exacerbation with or without hospitalization in the previous 12 months,  a 
smoking history of ≥10 pack/years, and one or more documented non-pulmonary chronic conditions 
(see ONLINE DATA SUPPLEMENT). These included congestive heart failure (CHF), ischemic 
heart disease (IHD), hypertension, hyperlipidemia and clinically significant sleep disordered 
breathing. Patients with significant visual disturbance or mental health disorders that would make 
them unable to use the monitoring platform, a planned prolonged absence from home, living in areas 
not covered by a mobile data network or those unable to use the study equipment were excluded. 
Patients were clinically stable with at least 4 weeks elapsed since their last exacerbation. 
All patients provided written informed consent and the protocol was approved by the ethical 
review boards of participating institutions.  
Protocol 
At recruitment, we recorded demographic data, measured spirometry before and 15 minutes 
after inhaling 200 µg salbutamol, and administered the St George’s Respiratory Questionnaire 
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(SGRQ), the COPD Assessment Tool (CAT)25, the EuroQoL EQ-5D questionnaire26 and the Patient 
Health Questionnaire (PHQ-9)27. Patients with CHF or IHD  also completed the Minnesota Living 
with Heart Failure Questionnaire (MLHFQ)28. 
Patients were shown how to use the study equipment and then randomized to intervention or 
control groups (1:1) using a concealed computer generated randomization sequence with a 4 element 
block design and stratified on a clinical centre basis. The intervention group used the CHROMED 
monitoring platform for nine months at approximately the same time each day. The platform 
comprised a device which measured within-breath respiratory mechanical impedance (RESMON 
PRO DIARY, Restech srl, Milan, Italy) using FOT, a touch-screen computer and a mobile modem. 
Patients with a diagnosis of CHF used an additional wearable device to assess blood pressure, oxygen 
saturation, heart rate and body temperature (WristClinic™ Medic4All, Switzerland) over a 4 minute 
period. FOT measurements were cleaned automatically from artefacts using previously published 
filtering rules29 and  automatically sent to the study server. An algorithm generated respiratory alerts 
if  a trend of worsening was detected in at least one of the following FOT parameters measured at 
5Hz: inspiratory resistance (Rinsp), inspiratory reactance (Xinsp) or the difference between 
inspiratory and expiratory reactance (∆Xrs), an index of the presence of tidal expiratory flow 
limitation30,31. Specifically, a worsening was deemed to occur when a statistically significant (p<0.05) 
linear increase of Rinsp or ∆Xrs or a decrease of Xinsp and a correlation coefficient of at least 0.4 
was detected in a time window of ten days including the current measurement (see ONLINE DATA 
SUPPLEMENT). Additional cardiac alerts were generated if blood pressure and/or heart rate and/or 
blood oxygen saturation and/or body temperature exceeded specific limits established in the baseline 
period on at least two consecutive days (see Table E2). Cardiac thresholds were adapted for each 
patient depending on baseline measurements. Missing FOT data were interpolated if at least 4 non-
consecutive FOT measurements in the past 10 days were present. Cardiac measurements were 
analysed if at least 2 consecutive days of data were present. The alert triggered a contact with the 
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study nurse to determine the patient’s clinical status and whether any intervention was required. After 
contact, a variety of actions were possible, ranging from no action to taking a course of antibiotics 
and/or corticosteroids or face-to-face assessment. We did not recommend specific criteria for 
hospitalisation, this decision being made on clinical grounds by the reviewing physician. Technical 
alerts were issued if no data were recorded for more than two days. When this occurred, the local site 
contacted the study patient. Patients in the control group received usual care according to their local 
practice.  
Every three months, all participants were telephoned to establish their use of 
antibiotic/corticosteroids (moderate COPD exacerbations) and primary care resources, and to 
complete the EQ-5D questionnaire. Every two months, participants were telephoned and completed 
the CAT, PHQ-9 and MLHFQ questionnaires. Hospital admissions were identified from clinical 
records at the end of the trial. A detailed description of the study protocol is provided in the ONLINE 
DATA SUPPLEMENT. 
Study outcomes 
The pre-defined co-primary endpoints were TTFH and change in the EQ-5D utility index 
score. Secondary outcomes included moderate exacerbation rate, hospitalisation, final scores of the 
CAT, PHQ-9 and MLHFQ questionnaires. A cost-utility analysis was also performed to measure 
whether the intervention was cost-effective by comparing healthcare costs and quality-adjusted life 
years (QALYs) in the two groups. Costs were analysed with a healthcare system perspective and 
included hospital and primary care resources, remote follow-ups and management of medical alarms. 
Since the platform was still a prototype, the costs of the equipment and technical support could not 
be included (see ONLINE DATA SUPPLEMENT).  We defined re-hospitalisation as any hospital 
admission that occurred during the study period after the first hospitalization. 
Sample size 
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Two main outcomes were chosen for this study. Assuming that 60% of the study population 
would not be hospitalized at 9 months32, a study population of 310 patients was calculated to detect 
a 25% increase in the TTFH with a type I error risk of 0.05 and a power of 80%. Moreover, using 
0.73±0.22 as an estimate of the expected EQ-5D utility score in the study population26 and 
anticipating a 10% drop out rate and 5% mortality rate, a sample size of at least 148 patients was 
needed to evaluate a minimum detectable difference of 15% of the EQ-5D utility score, with the same 
level of type I error and power used for TTFH.  
Statistical analysis 
Data are expressed as median and interquartile range (IQR) unless otherwise stated and were 
analysed by intention-to-treat. Time to first hospitalization used the Kaplan-Maier survival plot. 
Between-group significance was tested with the logrank test. Rates of prescription of 
antibiotics/corticosteroids (moderate exacerbations), hospital admissions and re-admission for COPD 
were calculated assuming a negative binomial distribution with number of events as the outcome, 
study group as single covariate and the logarithm of time of observation as offset variable33. Between-
group comparisons are expressed as incidence rate ratios (IRR). We considered a p value below 5% 
to be significant for the primary outcomes and all other p values to be exploratory if the primary 
outcomes were negative. 
An exploratory subgroup analysis was performed in patients with a potentially higher risk of 
hospitalization defined by: (1) a diagnosis of CHF and/or IHD, (2) COPD GOLD grade III and IV24, 
(3) at least two exacerbations in the year preceding the study, and (4) at least one hospital admission 
due to a COPD exacerbation in the year before the study.  
All statistical analyses were performed by using IBM SPSS Statistics (IBM SPSS, New York, 
NY, USA). A full description of the methodology used is reported in the ONLINE DATA 
SUPPLEMENT. 
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Results 
Patients were recruited from Oct 15, 2013 to Jul 3, 2015. Of 326 patients screened, 14 declined 
to participate due to concerns about the equipment or inability to perform the measurements. A total 
of 312 patients (75 from UK, 80 from Estonia, 63 from Sweden, 61 from Spain and 33 from Slovenia) 
were randomized (154 intervention, 158 control). Of those, 109 (71%) in the intervention and 122 
(77%) in the control group were successfully monitored for 9 months (Figure 1).  Overall, 88% (IQR: 
77%-95%) of the expected daily FOT measurements and 93% (IQR: 63%-98%) of the additional 
cardiac measurements for patients with cardiac co-morbidities were completed.  
Baseline demographics 
The groups were well matched for anthropometrics, disease severity, prior exacerbations, 
hospitalizations, co-morbidity and the season they entered the study (Table 1). Enrolled patients had 
a median age of 71 years, 97% had one or more co-morbidity which were predominantly 
cardiovascular, 49.7% had moderate, 37.2% severe and 13.1% very severe COPD24. All patients had 
exacerbated in the past year and 60.9% twice or more. Only 41.3% were hospitalized with a COPD 
exacerbation in the previous year. 
Medical alerts 
All the patients in the intervention group performed daily FOT measurements and 37 (24%) 
performed additional daily cardiac assessments. On average, 0.5 (IQR: 0.3–0.9) alerts/patient /month 
were generated based on FOT parameters, 1.1 (IQR: 0.8–1.4) alerts/patient/month by change in the 
cardiac parameters. Alerts were followed by a call from the study nurse within 1.4 ± 3.7 days of their 
generation. In 4039 days out of 36600 days of FOT monitoring (11%) and 1164 days out of 8406 
days of cardiac monitoring (14%) the system could not generate any alerts due to missing 
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measurements. Missing data were primarily due to patient forgetfulness or being in vacation/out of 
the town (45%), bad coverage of the mobile network preventing a stable data transmission (35%), 
technical failure of the monitoring equipment (18%) and hospitalization of the patient (3%). In half 
of the respiratory alerts, patients reported one or more symptom changes, including increased 
breathlessness (66%), increased cough (42%), loss of energy (35%) and increased wheeze or chest 
tightness (28%). A similar proportion of cardiac alerts were symptomatic, with breathlessness (15%) 
and loss of energy (18%) the most frequent problems. Respiratory and cardiac alerts led to a change 
of treatment or face-to-face visit in 34% and 37% of cases, respectively. Further detail is shown in 
the ONLINE DATA SUPPLEMENT (Table E1). 
Healthcare utilization defined exacerbations 
In total, 38 (48%) hospital admissions in the intervention group had an alert in the preceding 
two weeks, and 21 (27%) were treated by the nurses/clinicians managing the alarm. Mean TTFH was 
224 days (IQR: 209-240) in the intervention group and 254 days (IQR: 240-270) in the control group 
(p=0.342) (Figure 2). There was no difference between groups in the rate of moderate exacerbations 
(1.74 vs. 1.52, p=0.499), hospitalization (0.79 vs. 0.99, p=0.276) or the number of patients free from 
hospital admission (71% vs. 74%, p= 0.599) (Figure 3). Compared to control, intervention patients 
who were hospitalised during the trial (n=41 and 45, respectively) were less than half as likely to be 
re-hospitalized (IRR 0.46, p=0.017). The average length of hospital stay for all cause hospitalisation 
was 4.0 (IQR:1.0 - 9.0) days for the control group and 1.0 (IQR:1.0 - 6.7) day for the monitored group 
(p=0.045). The total days hospitalised in the two groups were 669 days in the control group and 359 
in the monitored group. Patients provided with cardiac monitoring, generated 19 (24%) of the 
recorded hospital admissions. 
Quality of life and health status 
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There were no significant between-group differences in the EQ-5D, CAT, or PHQ-9 scores at 
9-month (Table 2) nor did the MLHF questionnaire scores differ in patients with CHF and/or IHD. 
Cost effectiveness 
There was no statistically significant change in QALYs between intervention and control 
groups (0.485 vs. 0.491, p=0.731; Table 2). There was a potentially significant reduction in the mean 
cost per patient in the intervention group compared to the control group (€3547 vs. €4831, p=0.011; 
Table 2). 
Subgroup analysis 
There were no significant differences between intervention and control group in the baseline 
characteristics of the subgroups (Table E4). There was no difference between treatments in TTFH 
and EQ-5D utility score at 9-months in any subgroup. However, monitored patients previously 
hospitalized for a COPD exacerbation showed a 53% reduction (p=0.017) in their observed 
hospitalization rate compared with the control group (Figure 3). There was no difference in QALYs 
between intervention and control groups in any subgroup. The mean cost per patient in the 
intervention group was lower than in the control group for all the analysed subgroups except for the 
subgroup with severe or very severe COPD. The largest differences were seen in patients with a 
previous hospitalization with COPD (€4147 vs. €6949, p=0.008) and those with cardiac comorbidities 
(€4237 vs. €6520, p=0.014). 
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Discussion  
This is the first randomised trial to test whether daily tele-monitoring with objective 
measurements of resting lung function and cardiac variables (where appropriate) can detect COPD 
exacerbations early and reduce the chance of hospitalisation. Despite the acceptability of the 
monitoring system to patients, with a high adherence rate, its use did not affect overall TTFH, 
admission rate or patient’s quality of life assessed by EQ5D. However, there was a potential for 
reduced healthcare costs, mostly due to a 54% decrease in repeat hospital admissions without any 
increase in other healthcare costs. The cost difference varied between patients, being greatest in those 
who were hospitalised in the previous year.  
Although a few studies have suggested that combining symptoms and physiological variables, 
such as pulse and oxygen saturation, can identify COPD exacerbations34, subsequent randomised 
trials have not shown any effect of monitoring on TTFH and/or patient’s quality of life, similar to our 
findings11–13,15,16. However, while other trials recruited previously hospitalised patients, we studied 
COPD patients reporting two or more exacerbations in the previous year, i.e. a broader group of less 
severe patients. Although we saw no difference between groups in the time to first hospitalisation 
(our primary study end point), there was a difference in the mean duration of hospital stay and the 
total days hospitalised after an emergency admission in favour of the monitored patients. 
Exacerbation duration is an important determinant of the risk for future exacerbation and disease 
progression35 and this may explain why patients who were hospitalised during the trial were 
significantly less likely to have a further hospitalisation when they were monitored. When we 
restricted our analysis to patients hospitalised in the year before enrolment, a group at higher risk of 
subsequent hospitalisation, there was a 53% reduction in hospitalisation rate in monitored patients. 
This effect on re-hospitalization may relate to the need for a run-in period to maximise the benefit of 
tele-monitoring or to a reduction in exacerbation severity during the first or subsequent 
13 
 
hospitalisations. This latter effect may result from earlier detection of exacerbations as there is 
evidence that earlier treatment decreases the duration of exacerbations36.  
We based respiratory alerts on daily measurements of lung mechanics by tidal oscillatory 
mechanics, thereby automating the system and reducing dependence on the patient’s self-reported 
symptoms37. The CHROMED tele-monitoring system detected changes that preceded half the 
hospitalisations early enough to permit intervention Not all of these alerts identified events considered 
important by the clinical staff, although some alerts did precede subsequent hospitalisation, even 
when no extra treatment was given. Our data support other observations on the diversity of time 
course and response to treatment of COPD exacerbations38,39. 
Patients with COPD were able to perform daily lung function measurements during tidal 
breathing over an extended period with high adherence rate (88% recordings completed) and low 
drop out (73% completed the study). The attrition rate was similar between groups and little different 
to comparable clinical trials performed on similar patients and duration (23%40,  50%12 , 22%11). As 
there was no difference between study arms we can hypothesise that the attritions were mostly due to 
the multiple contacts for collecting questionnaires and the feeling of limitation in freedom to act 
induced by participating in a clinical trial rather than specific issues related to the monitoring 
procedures. The number of respiratory alerts per patients was roughly one every two months, a small 
number compared to other similar telemonitoring trials in which alerts were based on symptoms 
and/or other variables11,12,41. Compared to those studies, the monitoring system based on continuous 
self-evaluation of lung function by FOT led to neither a major increase in time burden for healthcare 
personnel nor an increase in drug prescriptions when compared to standard practice, allowing it to be 
incorporated into a clinical service. Despite being used in a smaller group of patients, the cardiac 
monitor generated more alerts (1 alert/patient/month instead of the 0.5 alert/patients/month generated 
by FOT monitoring), similar to other studies11 that resulted in more changes in therapy. However, the 
number of hospitalisations in this group of patients was similar to the other patients.   
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At present, the economic benefit of tele-monitoring in COPD remains unclear 42, reflecting 
the difficulty in isolating the effects of tele-monitoring from educational interventions43.It is 
important to be cautious when interpreting data from a trial whose primary end points were not met 
as is the case with CHROMED. Nonetheless, applying our pre-specified health economic analysis 
suggested that there was a reduction in the healthcare costs in the intervention arm, with an average 
saving of €1712 (27% lower) per patient per year, largely driven by a reduction in hospital costs. 
Although the additional costs for the hospital to manage the alerts were included in the analysis, the 
costs of the equipment and technical support were not included, as the CHROMED platform was still 
a prototype. Equipment and technical support costs tend to differ across countries and are often the 
result of a negotiation process between hospital and provider according different factors such as 
volumes. For tele-monitoring to be truly cost-effective the annual cost of equipment and technical 
support must be less than the annualized difference in costs between intervention and control groups. 
Using previously published values as an estimate of the yearly costs for installation, training and 
maintenance (€58)17 and  €53 for broadband contract (estimate from the trial), the system would be 
cost effective if the annual rental/purchase costs of the equipment were less than  €1600 per patient. 
Our exploratory subgroup analyses considered patients at greater risk of hospitalization, who 
might benefit more from tele-monitoring. Previously hospitalised patients showed the largest cost 
savings exclusive of equipment costs (3736 €/patient/year) suggesting that future studies should target 
this population. In patients with cardiac disease, there was a similar reduction in hospitalisation 
though this difference did not reach even notional significance. 
Limitations of the study 
The size and objective nature of the monitoring system are particular strengths of our study. 
However we were limited by the lower than expected number of hospitalisation and the variation in 
the pattern of healthcare between health care systems which precluded our mandating specific 
interventions in response to an alert. There may have been differences in the threshold for 
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hospitalization and we did not have an independent study endpoint committee to review the causes 
of death. Inevitably in a study of this kind both the participants and study team were unblinded to the 
nature of the intervention. However data about health care resource utilisation was obtained and 
analysed independently of the clinical study team.  
To avoid bias from variation in costs across countries and improve its robustness, the 
economic evaluation was based on the costs of each intervention in a single country (UK)44,45. The 
actual magnitude of the cost savings should therefore be adjusted when different healthcare systems 
are considered. Moreover, the costs of the equipment and technical support should be carefully taken 
into account as and when the prototype platform is marketed. As a relatively small number of patients 
(24%) used the cardiac monitoring system, we cannot assess the cost effectiveness of this tool.   
Conclusions 
We found that tele-monitoring of older COPD patients, using forced oscillation methodology 
together with cardiac monitoring in patients with significant cardiac co-morbidities, was practical, 
well-tolerated and acceptable. Tele-monitoring did not influence TTFH, or our measure of general 
health status, the primary study outcomes. However, there were fewer exacerbations in patients with 
recent hospitalisations and fewer re-admissions in those who were hospitalised, changes which could 
translate into a health economic gain depending on the costs of any commercialised system.  Whether 
cardiac monitoring in selected patients confers additional benefit is unclear and merits further study. 
Although ours was a negative clinical trial, it strongly suggests that using objectively defined criteria 
for clinical deterioration may be of value in COPD patients at risk of hospitalisation and this group 
should be the focus of future investigations. 
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Tables  
Table 1 - Baseline characteristics of study patients. 
 Control (n=158) 
Intervention 
(n=154) 
Gender, Male/Female 105/53 101/53 
Age, median (IQR), years 71.0 (65.3, 76.0) 71.0 (66.0, 75.8) 
BMI, median (IQR), Kg/m2 26.9 (23.8, 31.6) 27.7 (24.5, 30.8) 
Smoking History, median (IQR), pack/years 40.5 (30.0, 56.0) 40.0 (23.1, 50.0) 
FEV1, median (IQR), L 1.32 (0.94, 1.77) 1.26 (0.96, 1.65) 
FEV1, median (IQR), %predicted 50.4 (38.0, 63.9) 49.4 (37.1, 59.2) 
FVC, median (IQR), L 2.52 (2.08, 3.07) 2.55 (2.01, 3.10) 
FVC, median (IQR), %predicted 75.8 (63.0 89.7) 73.8 (61.8, 88.0) 
FEV1/FVC,  median (IQR), ratio 0.53 (0.42, 0.62) 0.53 (0.39, 0.63) 
St. George's Respiratory Questionnaire, median (IQR), 
total score 50.9 (34.7, 63.4) 46.2 (35.6, 64.3) 
No (%) of patient with only one exacerbation in the 
previous year 59 (37) 63 (41) 
No (%) of patient with more than one exacerbation in the 
previous year 99 (63) 91 (59) 
No (%) of patient with one exacerbation in the previous 3 
months 66 (42) 50 (32) 
No (%) of patient with more than one exacerbation in the 
previous 3 months 22 (14) 25 (16) 
No (%) of patients hospitalized in the previous year 65 (41) 64 (42) 
No (%) of patients hospitalized in the previous 3 months 21 (13) 22 (14) 
No (%) of patient at GOLD stage (GOLD 2006)   
  I 3 (2) 4 (3) 
  II 76 (48) 72 (47) 
  III 61 (39) 55 (36) 
  IV 18 (11) 23 (15) 
Season recruited, No (%)   
  Spring 8 (5) 7 (5) 
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  Summer 17 (11) 13 (8) 
  Autumn 78 (49) 78 (51) 
  Winter 55 (35) 56 (36) 
No (%) of patient with the following comorbidities   
  Congestive heart failure (CHF) 13 (8) 18 (12) 
  Ischemic heart disease (IHD) 36 (23) 38 (25) 
  Congestive heart failure (CHF)+ischemic heart disease 
(IHD) 21 (13) 19 (12) 
  Hypertension 108 (68) 111 (72) 
  Sleep related disordered breathing  10 (6) 17 (11) 
  Osteoporosis 23 (15) 26 (17) 
  Hyperlipidaemia 92 (58) 82 (53) 
No of comorbidities per patient 2.0 (1.0, 3.0) 2.0 (1.0, 3.0) 
Health status and depression questionnaires   
  EQ-5D utility score, mean (SD) 0.663 (.225) 0.641 (.224) 
  EQ-5D VAS, mean (SD) 57.32 (20.72) 58.80 (17.76) 
  CAT score, mean (SD) 17.75 (8.42) 17.38 (7.87) 
  PHQ-9 score, mean (SD) 5.97 (5.79) 6.27 (5.69) 
  MLHF score, mean (SD) 27.82 (17.39) 31.83 (22.14) 
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Table 2 – Corticosteroids/antibiotics prescription rates, hospitalization and re–hospitalisation rates, 
cost per patient and health status and depression questionnaire results 
All patients Control (n=158) 
Intervention 
(n=154) p value 
Prescription rate of systemic 
corticosteroids/antibiotics, events/year 1.515 1.735 0.499 
Hospitalization rate, admission/year 0.99 0.79 0.276 
No of patients free from hospital admission (%) 117 (74) 109 (71) 0.599 
Length of hospitalization, median (IQR), days  4.0 (1.0, 9.0) 1.0 (1.0, 6.7) 0.045 
Re-hospitalisation, IRR (95% CI) 0.46 (0.24 – 0.87) 0.017 
EQ-5D (n=153) (n=150)  
  Utility score (9-month), mean (SD) .640 (.248) .637 (.225) 0.915 
  VAS (9-month), mean (SD) 55.75 (21.17) 55.35 (18.46) 0.869 
CAT (n=154) (n=150)  
  Score (8-month), mean (SD) 17.17 (8.33) 16.76 (7.71) 0.665 
PHQ-9 (n=155) (n=150)  
  Score (8-month), mean (SD) 6.35 (5.45) 6.71 (5.92) 0.606 
MLHF (n=33) (n=35)  
  Score (8-month), mean (SD) 33.99 (16.94) 34.75 (19.66) 0.887 
Cost utility analysis (n=153) (n=150)  
  QALYs (9-month), mean (SD) .485 (.142) .491 (.164) 0.731 
  Cost per patient (9-month), €, mean (SD) 4831 (10250) 3547 (5038) 0.011 
Patients with CHF and/or IHD Control (n=70) 
Intervention 
(n=75) 
 
Prescription rate of systemic 
corticosteroids/antibiotics, events/year 1.82 2.19 
0.499 
Hospitalization rate, admission/year 1.40 0.73 0.067 
No of patients free from hospital admission (%) 48 (69) 57 (76) 0.418 
QALYs (9-month), mean (SD) 0.433 (0.192) 0.430 (0.185) 0.971 
Cost per patient (9-month), €, mean (SD) 6520 (12575) 4237 (6154) 0.014 
COPD severe and very severe Control (n=79) 
Intervention 
(n=78) 
 
Prescription rate of systemic 
corticosteroids/antibiotics, events/year 2,07 2,27 
0.699 
Hospitalization rate, admission/year 1.36 1.16 0.582 
No of patients free from hospital admission (%) 52 (66) 48 (62) 0.693 
QALYs (9-month), mean (SD) 0.484 (0.176) 0.473 (0.153) 0.68 
Cost per patient (9-month), €, mean (SD) 5704 (10717) 4362 (6072) 0.116 
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Frequent exacerbators Control (n=99) 
Intervention 
(n=91) 
 
Prescription rate of systemic 
corticosteroids/antibiotics, events/year 2,06 2,22 
0.645 
Hospitalization rate, admission/year 1.36 0.90 0.133 
No of patients free from hospital admission (%) 67 (74) 59 (65) 0.788 
QALYs (9-month), mean (SD) 0.457 (0.191) 0.450 (0.145) 0.842 
Cost per patient (9-month), €, mean (SD) 5798 (12221) 3847 (5778) 0.010 
Hospitalized in the past year Control (n=65) 
Intervention 
(n=64) 
 
Prescription rate of systemic 
corticosteroids/antibiotics, events/year 1,95 1,72 
0.779 
Hospitalization rate, admission/year 1.88 0.85 0.017 
No of patients free from hospital admission (%) 38 (58) 43 (67) 0.401 
QALYs (9-month), mean (SD) 0.428 (0.203) 0.418 (0.172) 0.868 
Cost per patient (9-month), €, mean (SD) 6949 (11870) 4147 (6482) 0.008 
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Figure 1 – CONSORT diagram showing the flow of patients throughout the study and reason 
for drop out 
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Figure 2 – Time to first hospital admission in control (continuous line) and 
intervention group (dashed, dark grey line). No significant difference was seen 
comparing the two groups. 
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Figure 3 – Incidence rate ratio (IRR) of hospitalizations (panel A) and systemic 
corticosteroids/antibiotics prescriptions (panel B) in all patients and exploratory 
subgroups.  
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